|
1
|
Davies L and Welch HG: Current thyroid
trends in the United States. JAMA Otolaryngol Head Neck Surg.
140:317–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lam AK, Lo CY and Lam KS: Papillary
carcinoma of thyroid: A 30-yr clinicopathological review of the
histological variants. Endocr Pathol. 16:323–330. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hawk WA and Hazard JB: The many
appearances of papillary carcinoma of the thyroid. Cleve Clin Q.
43:207–215. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
LiVolsi VA: Papillary carcinoma tall cell
variant (TCV): A review: Endocr Pathol. 21:12–15. 2010.
|
|
5
|
Lastra RR, LiVolsi VA and Baloch ZW:
Aggressive variants of follicular cell-derived thyroid carcinomas.
A cytopathologis's perspective. Cancer Cytopathol. 122:484–503.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
LiVolsi VA, Albores-Saavedra J, Asa SL,
Baloch ZW, Sobrinho-Simões M, Wenig B, DeLellis RA, Cady B,
Mazzaferri EL, Hay I, Fagin JA, et al: Papillary carcinomaDeLellis
RA, Heitz PU and Eng C: Pathology and Genetics: Tumours of
Endocrine Organs. 3rd. World Health Organization Classification of
Tumours. France. IARC Press; Lyon: pp. 57–66. 2004
|
|
7
|
Ghossein R and Livolsi VA: Papillary
thyroid carcinoma tall cell variant. Thyroid. 18:1179–1181. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ganly I, Ibrahimpasic T, Rivera M, Nixon
I, Palmer F, Patel SG, Tuttle RM, Shah JP and Ghossein R:
Prognostic implications of papillary thyroid carcinoma with
tall-cell features. Thyroid. 24:662–670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dettmer MS, Schmitt A, Steinert H, Capper
D, Moch H, Komminoth P and Perren A: Tall cell papillary thyroid
carcinoma: New diagnostic criteria and mutations in BRAF and TERT.
Endocr Relat Cancer. 22:419–429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang X, Cheng W, Liu C and Li J: Tall cell
variant of papillary thyroid carcinoma: Current evidence on
clinicopathologic features and molecular biology. Oncotarget.
7:40792–40799. 2016.PubMed/NCBI
|
|
11
|
Morris LG, Shaha AR, Tuttle RM, Sikora AG
and Ganly I: Tall-cell variant of papillary thyroid carcinoma: A
matched-pair analysis of survival. Thyroid. 20:153–158. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Johnson TL, Lloyd RV, Thompson NW,
Beierwaltes WH and Sisson JC: Prognostic implications of the tall
cell variant of papillary thyroid carcinoma. Am J Surg Pathol.
12:22–27. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ghossein RA, Leboeuf R, Patel KN, Rivera
M, Katabi N, Carlson DL, Tallini G, Shaha A, Singh B and Tuttle RM:
Tall cell variant of papillary thyroid carcinoma without
extrathyroid extension: Biologic behavior and clinical
implications. Thyroid. 17:655–661. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi X, Liu R, Basolo F, Giannini R, Shen
X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, et al: Differential
clinicopathological risk and prognosis of major papillary thyroid
cancer variants. J Clin Endocrinol Metab. 101:264–274. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nikiforov YE, Seethala RR, Tallini G,
Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan
A, Kakudo K, et al: Nomenclature revision for encapsulated
follicular variant of papillary thyroid carcinoma: A paradigm shift
to reduce overtreatment of indolent tumors. JAMA Oncol.
2:1023–1029. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gnemmi V, Renaud F, Do Cao C, Salleron J,
Lion G, Wemeau JL, Copin MC, Carnaille B, Leteurtre E, Pattou F and
Aubert S: Poorly differentiated thyroid carcinomas: Application of
the Turin proposal provides prognostic results similar to those
from the assessment of high-grade features. Histopathology.
64:263–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer staging handbook. 7th. NY,
Springer; New York: pp. 111–122. 2010
|
|
18
|
Cameselle-Teijeiro J, Abdulkader I,
Pérez-Becerra R, Vázquez-Boquete A, Alberte-Lista L, Ruiz-Ponte C,
Forteza J and Sobrinho-Simões M: BRAF mutation in solid cell nest
hyperplasia associated with papillary thyroid carcinoma. A
precursor lesion? Hum Pathol. 40:1029–1035. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kazaure HS, Roman SA and Sosa JA:
Aggressive variants of papillary thyroid cancer: Incidence,
characteristics and predictors of survival among 43,738 patients.
Ann Surg Oncol. 19:1874–1880. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ceresini G, Corcione L, Michiara M, Sgargi
P, Teresi G, Gilli A, Usberti E, Silini E and Ceda GP: Thyroid
cancer incidence by histological type and related variants in a
mildly iodine-deficient area of Northern Italy, 1998 to 2009.
Cancer. 118:5473–5480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guan H, Vandenbussche CJ, Erozan YS,
Rosenthal DL, Tatsas AD, Olson MT, Zheng R, Auger M and Ali SZ: Can
the tall cell variant of papillary thyroid carcinoma be
distinguished from the conventional type in fine needle aspirates?
A cytomorphologic study with assessment of diagnostic accuracy.
Acta Cytol. 57:534–542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Axelsson TA, Hrafnkelsson J, Olafsdottir
EJ and Jonasson JG: Tall cell variant of papillary thyroid
carcinoma: A population-based study in Iceland. Thyroid.
25:216–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ito Y, Hirokawa M, Fukushima M, Inoue H,
Yabuta T, Uruno T, Kihara M, Higashiyama T, Takamura Y, Miya A, et
al: Prevalence and prognostic significance of poor differentiation
and tall cell variant in papillary carcinoma in Japan. World J
Surg. 32:1535–1545. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Terry JH, St John SA, Karkowski FJ, Suarez
JR, Yassa NH, Platica CD and Marti JR: Tall cell papillary thyroid
cancer: Incidence and prognosis. Am J Surg. 168:459–461. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rüter A, Nishiyama R and Lennquist S:
Tall-cell variant of papillary thyroid cancer: Disregarded entity?
World J Surg. 21:15–21. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Michels JJ, Jacques M, Henry-Amar M and
Bardet S: Prevalence and prognostic significance of tall cell
variant of papillary thyroid carcinoma. Hum Pathol. 38:212–219.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bernstein J, Virk RK, Hui P, Prasad A,
Westra WH, Tallini G, Adeniran AJ, Udelsman R, Sasaki CT, Roman SA,
et al: Tall cell variant of papillary thyroid microcarcinoma:
Clinicopathologic features with BRAF(V600E) mutational analysis.
Thyroid. 23:1525–1531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gilliland FD, Hunt WC, Morris DM and Key
CR: Prognostic factors for thyroid carcinoma. A population-based
study of 15,698 cases from the Surveillance, Epidemiology and End
Results (SEER) program 1973–1991. Cancer. 79:564–573. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kilfoy BA, Devesa SS, Ward MH, Zhang Y,
Rosenberg PS, Holford TR and Anderson WF: Gender is an age-specific
effect modifier for papillary cancers of the thyroid gland. Cancer
Epidemiol Biomarkers Prev. 18:1092–1100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Soares P, Celestino R, Melo M, Fonseca E
and Sobrinho-Simões M: Prognostic biomarkers in thyroid cancer.
Virchows Arch. 464:333–346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hay ID, Thompson GB, Grant CS, Bergstralh
EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL,
et al: Papillary thyroid carcinoma managed at the Mayo Clinic
during six decades (1940–1999): Temporal trends in initial therapy
and long-term outcome in 2444 consecutively treated patients. World
J Surg. 26:879–885. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Erler P, Keutgen XM, Crowley MJ, Zetoune
T, Kundel A, Kleiman D, Beninato T, Scognamiglio T, Elemento O,
Zarnegar R and Fahey TJ III: Dicer expression and microRNA
dysregulation associate with aggressive features in thyroid cancer.
Surgery. 156:1342–1350. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sobrinho-Simões M, Máximo V, Rocha AS,
Trovisco V, Castro P, Preto A, Lima J and Soares P: Intragenic
mutations in thyroid cancer. Endocrinol Metab Clin North Am.
37:333–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tavares C, Melo M, Cameselle-Teijeiro JM,
Soares P and Sobrinho-Simões M: ENDOCRINE TUMOURS: Genetic
predictors of thyroid cancer outcome. Eur J Endocrinol.
174:R117–R126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xing M, Alzahrani AS, Carson KA, Viola D,
Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, et al:
Association between BRAF V600E mutation and mortality in patients
with papillary thyroid cancer. JAMA. 309:1493–1501. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li F, Chen G, Sheng C, Gusdon AM, Huang Y,
Lv Z, Xu H, Xing M and Qu S: BRAFV600E mutation in papillary
thyroid microcarcinoma: A meta-analysis. Endocr Relat Cancer.
22:159–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jin L, Chen E, Dong S, Cai Y, Zhang X,
Zhou Y, Zeng R, Yang F, Pan C, Liu Y, et al: BRAF and TERT promoter
mutations in the aggressiveness of papillary thyroid carcinoma: A
study of 653 patients. Oncotarget. 7:18346–18355. 2016.PubMed/NCBI
|
|
38
|
Virk RK, Van Dyke AL, Finkelstein A,
Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa
JA, et al: BRAFV600E mutation in papillary thyroid microcarcinoma:
A genotype-phenotype correlation. Mod Pathol. 26:62–70. 2013.
View Article : Google Scholar : PubMed/NCBI
|
